Lv4
428 积分 2024-09-02 加入
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
9小时前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
9小时前
已完结
Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer
2个月前
已完结
Epigenetic inactivation and tumor suppressor activity of HAI‐2/SPINT2 in gastric cancer
6个月前
已完结
Inhibition of TMPRSS2 by HAI-2 reduces prostate cancer cell invasion and metastasis
6个月前
已完结
Long noncoding RNA PEG10 regulates proliferation and invasion of esophageal cancer cells
6个月前
已完结
SERPINE2 promotes esophageal squamous cell carcinoma metastasis by activating BMP4
6个月前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
7个月前
已完结
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
7个月前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
7个月前
已完结
皖公网安备34019202002308
